Cingulate Inc. (CING) 10-Year Financial Performance & Capital Metrics

CING • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutCingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.Show more

Revenue $0
EBITDA -$15M +32.4%
Net Income -$16M +33.9%
EPS (Diluted) -10.20 +96.7%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -5305.02%
ROIC -
Debt/Equity 0.68
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 68.4% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-27.97%

EPS CAGR

10Y-

5Y-

3Y-

TTM80.46%

ROCE

10Y Avg-929.5%

5Y Avg-1015.41%

3Y Avg-1535.93%

Latest-990.8%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	178.91K	842.35K	808.44K	621.99K	582.92K	653.09K
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	-178.91K	-842.35K	-808.44K	-621.99K	-582.92K	-653.09K
Gross Margin %	-	-	-	-	-	-
Gross Profit Growth %	-	-3.71%	0.04%	0.23%	0.06%	-0.12%
Operating Expenses+	11.47M	6.24M	19.87M	16.88M	22.18M	14.99M
OpEx % of Revenue	-	-	-	-	-	-
Selling, General & Admin	2.37M	1.15M	12.27M	8.51M	7.27M	5.55M
SG&A % of Revenue	-	-	-	-	-	-
Research & Development	9.09M	5.09M	8.41M	9M	15.49M	9.45M
R&D % of Revenue	-	-	-	-	-	-
Other Operating Expenses	0	0	-808.53K	-621.99K	-583.03K	0
Operating Income+	-11.65M	-7.08M	-20.68M	-17.5M	-22.76M	-15.64M
Operating Margin %	-	-	-	-	-	-
Operating Income Growth %	-	0.39%	-1.92%	0.15%	-0.3%	0.31%
EBITDA+	-11.47M	-6.24M	-19.87M	-16.88M	-22.18M	-14.99M
EBITDA Margin %	-	-	-	-	-	-
EBITDA Growth %	-	0.46%	-2.18%	0.15%	-0.31%	0.32%
D&A (Non-Cash Add-back)	178.91K	842.35K	808.44K	621.99K	582.92K	653.09K
EBIT	-11.55M	-7.13M	-20.68M	-17.68M	-23.53M	-15.55M
Net Interest Income+	0	-54.6K	-33.41K	-173.82K	775.76K	0
Interest Income	101	100	0	175	775.76K	0
Interest Expense	0	54.6K	33.41K	174K	0	0
Other Income/Expense	100.96K	-100.25K	-30.59K	-174.51K	-775.76K	99.24K
Pretax Income+	-11.55M	-7.18M	-20.71M	-17.68M	-23.53M	-15.55M
Pretax Margin %	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-11.55M	-7.18M	-20.74M	-17.68M	-23.53M	-15.55M
Net Margin %	-	-	-	-	-	-
Net Income Growth %	-	0.38%	-1.89%	0.15%	-0.33%	0.34%
Net Income (Continuing)	-11.55M	-7.18M	-20.71M	-17.68M	-23.53M	-15.55M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-242.89	-12.70	-55.80	-31.20	-311.99	-10.20
EPS Growth %	-	0.95%	-3.39%	0.44%	-9%	0.97%
EPS (Basic)	-242.89	-12.70	-55.80	-31.20	-311.99	-10.20
Diluted Shares Outstanding	1.41M	1.41M	1.41M	1.41M	2.26M	3.81M
Basic Shares Outstanding	1.41M	1.41M	1.41M	1.41M	2.26M	3.81M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	978.32K	1.79M	18.88M	7.87M	578.59K	12.66M
Cash & Short-Term Investments	437.19K	1.2M	16.49M	5.36M	52.42K	12.21M
Cash Only	418.47K	1.2M	16.49M	5.36M	52.42K	12.21M
Short-Term Investments	18.72K	933	933	0	0	0
Accounts Receivable	113.24K	151.77K	690.25K	234.43K	14.62K	26.32K
Days Sales Outstanding	-	-	-	-	-	-
Inventory	0	0	0	100.34K	0	0
Days Inventory Outstanding	-	-	-	58.88	-	-
Other Current Assets	0	0	0	1.64M	490.86K	368.29K
Total Non-Current Assets+	4.3M	4M	4M	3.54M	2.91M	2.2M
Property, Plant & Equipment	4.16M	4M	4M	3.54M	2.91M	2.2M
Fixed Asset Turnover	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	143.02K	0	-1.36B	-5.91B	0	0
Total Assets+	5.28M	5.79M	22.89M	11.41M	3.49M	14.86M
Asset Turnover	-	-	-	-	-	-
Asset Growth %	-	0.1%	2.95%	-0.5%	-0.69%	3.26%
Total Current Liabilities+	2.95M	3.36M	1.18M	7.01M	10.23M	4.97M
Accounts Payable	1.9M	975.11K	264.69K	762.36K	5.2M	1.27M
Days Payables Outstanding	3.87K	422.53	119.5	447.37	3.26K	709.94
Short-Term Debt	0	500.33K	310.69K	5M	3M	2.53M
Deferred Revenue (Current)	524.03K	0	601.3K	0	0	0
Other Current Liabilities	-368.54K	234.17K	-336.67K	719.01K	593.02K	355.48K
Current Ratio	0.33x	0.53x	16.05x	1.12x	0.06x	2.55x
Quick Ratio	0.33x	0.53x	16.05x	1.11x	0.06x	2.55x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	1.71M	1.13M	866.04K	510.24K	135.1K	2.44M
Long-Term Debt	0	0	0	0	0	2.44M
Capital Lease Obligations	1.71M	1.11M	866.04K	510.24K	135.1K	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	23.61K	0	0	0	0
Total Liabilities	4.66M	4.5M	2.04M	7.52M	10.36M	7.41M
Total Debt+	2.09M	2.05M	1.19M	5.87M	3.51M	5.1M
Net Debt	1.67M	848.99K	-15.3M	509.77K	3.46M	-7.11M
Debt / Equity	3.39x	1.58x	0.06x	1.51x	-	0.68x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-	-129.72x	-619.01x	-100.58x	-	-
Total Equity+	615.88K	1.29M	20.84M	3.88M	-6.87M	7.46M
Equity Growth %	-	1.1%	15.13%	-0.81%	-2.77%	2.09%
Book Value per Share	0.44	0.91	14.74	2.75	-3.04	1.96
Total Shareholders' Equity	615.88K	1.29M	20.84M	3.88M	-6.87M	7.46M
Common Stock	615.85K	32.31M	1.13K	61	10	340
Retained Earnings	0	-31.02M	-51.73M	-69.41M	-92.94M	-108.49M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	32	165	165	0	0	0
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.53M	-6.81M	-10.43M	-15.88M	-15.03M	-18.45M
Operating CF Margin %	-	-	-	-	-	-
Operating CF Growth %	-	0.29%	-0.53%	-0.52%	0.05%	-0.23%
Net Income	-11.55M	-7.18M	-20.71M	-17.68M	-23.53M	-15.55M
Depreciation & Amortization	178.91K	666.03K	708.32K	394.01K	582.92K	653.09K
Stock-Based Compensation	0	0	12.78M	800.8K	812.67K	995.48K
Deferred Taxes	0	0	-16.26M	-797.96K	0	0
Other Non-Cash Items	-48.05K	0	16.26M	797.96K	0	0
Working Capital Changes	1.88M	-293.49K	-3.21M	598.62K	7.1M	-4.55M
Change in Receivables	-71.83K	-38.53K	-1.86M	1.25M	219.81K	-11.7K
Change in Inventory	-725.61K	0	0	-1.25M	0	0
Change in Payables	1.7M	0	0	791K	0	0
Cash from Investing+	2.74M	-384.17K	-814.74K	-152.65K	-224.1K	-211.8K
Capital Expenditures	-1.02M	-402.1K	-814.74K	-153.42K	-224.1K	-211.8K
CapEx % of Revenue	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	3.76M	0	0	-165	0	0
Cash from Financing+	6.14M	7.97M	26.54M	4.9M	9.95M	30.82M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	6.14M	7.51M	7.1M	0	0	0
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-10.55M	-7.21M	-11.25M	-16.04M	-15.26M	-18.66M
FCF Margin %	-	-	-	-	-	-
FCF Growth %	-	0.32%	-0.56%	-0.43%	0.05%	-0.22%
FCF per Share	-7.46	-5.10	-7.96	-11.34	-6.74	-4.90
FCF Conversion (FCF/Net Income)	0.83x	0.95x	0.50x	0.90x	0.64x	1.19x
Interest Paid	0	50.23K	0	0	19.42K	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-1874.76%	-752.88%	-187.39%	-142.98%	-	-5305.02%
Return on Invested Capital (ROIC)	-	-239.93%	-403.68%	-264.26%	-3482.89%	-
Debt / Equity	3.39x	1.58x	0.06x	1.51x	-	0.68x
Interest Coverage	-	-129.72x	-619.01x	-100.58x	-	-
FCF Conversion	0.83x	0.95x	0.50x	0.90x	0.64x	1.19x

Frequently Asked Questions

Growth & Financials

Cingulate Inc. (CING) grew revenue by 0.0% over the past year. Growth has been modest.

Cingulate Inc. (CING) reported a net loss of $22.1M for fiscal year 2024.

Dividend & Returns

Cingulate Inc. (CING) has a return on equity (ROE) of -5305.0%. Negative ROE indicates the company is unprofitable.

Cingulate Inc. (CING) had negative free cash flow of $17.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener